United Kingdom (UK)
Recombinant monoclonal antibody to Occludin. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 67-2.
UniProt Accession Number of Target Protein: Q16625
Alternative Name(s) of Target: OCLN
Immunogen: The original antibody was generated by immunizing mice with KLH-coupled, modified hOCLN-EC2 peptide. The modification made to the hOCLN-EC2 peptide was an added cysteine residue was at the N-terminal end.
Specificity: This antibody is specific for the peptide ALCNQFYTPAATGLYVD, which is part of the second extracellular loop (EL2) of human OCLN (aa 214-230). However, it has also been shown to bind mouse OCLN, strongly suggesting that it does not recognize the human-specific amino acids in OCLN-EC2.
Application Notes: The original format of this antibody (mouse IgG1) can bind hOCLN, as was determined by ELISA during initial hybridoma screening. This antibody efficiently inhibited HCV infection in the HCV-permissive human cell line Huh7.5.1. This antibody can access OCLN from the basolateral side of hepatocytes but not from the apical side using three different culture systems of Huh7.5.1 cells. This antibody was shown to cross-react with mouse OCLN in a WB. This antibody showed no adverse effects on cell viability or the barrier function of tight junctions (Okai et al., 2018; PMID: 29682171).
Antibody first published in:
Okai et al. A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro Oncotarget. 2018 Mar 30;9(24):16588-16598. doi: 10.18632/oncotarget.24742. PMID:29682171
Note on publication:
The original publication discusses the development of an anti-human occludin (hOCLN) monoclonal antibody (mAb) 67-2 and its potential as a target for preventing and treating HCV infection.